Cargando…

Long-term follow-up after transoral outlet reduction following Roux-en-Y gastric bypass: Back to stage 0?

Background and study aims  Significant weight regain affects up to one-third of patients after Roux-en-Y gastric bypass (RYGB) and demands treatment. Transoral outlet reduction (TORe) with argon plasma coagulation (APC) alone or APC plus full-thickness suturing TORe (APC-FTS) is effective in the sho...

Descripción completa

Detalles Bibliográficos
Autores principales: Brunaldi, Vitor Ottoboni, Peixoto de Oliveira, Guilherme Henrique, Kerbage, Anthony, Ribas, Pedro Henrique, Nunes, Felipe, Faria, Galileu, de Moura, Diogo, Riccioppo, Daniel, Santo, Marco, de Moura, Eduardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219785/
https://www.ncbi.nlm.nih.gov/pubmed/37251791
http://dx.doi.org/10.1055/a-2075-1198
_version_ 1785049089140850688
author Brunaldi, Vitor Ottoboni
Peixoto de Oliveira, Guilherme Henrique
Kerbage, Anthony
Ribas, Pedro Henrique
Nunes, Felipe
Faria, Galileu
de Moura, Diogo
Riccioppo, Daniel
Santo, Marco
de Moura, Eduardo
author_facet Brunaldi, Vitor Ottoboni
Peixoto de Oliveira, Guilherme Henrique
Kerbage, Anthony
Ribas, Pedro Henrique
Nunes, Felipe
Faria, Galileu
de Moura, Diogo
Riccioppo, Daniel
Santo, Marco
de Moura, Eduardo
author_sort Brunaldi, Vitor Ottoboni
collection PubMed
description Background and study aims  Significant weight regain affects up to one-third of patients after Roux-en-Y gastric bypass (RYGB) and demands treatment. Transoral outlet reduction (TORe) with argon plasma coagulation (APC) alone or APC plus full-thickness suturing TORe (APC-FTS) is effective in the short term. However, no study has investigated the course of gastrojejunostomy (GJ) or quality of life (QOL) data after the first post-procedure year. Patients and methods  Patients eligible for a 36-month follow-up visit after TORe underwent upper gastrointestinal endoscopy with measurement of the GJ and answered QOL questionnaires (RAND-36). The primary aim was to evaluate the long-term outcomes of TORe, including weight loss, QOL, and GJ anastomosis (GJA) size. Comparisons between APC and APC-FTS TORe were a secondary aim. Results  Among 39 eligible patients, 29 returned for the 3-year follow-up visit. There were no significant differences in demographics between APC and APC-FTS TORe groups. At 3 years, patients from both groups regained all the weight lost at 12 months, and the GJ diameter was similar to the pre-procedure assessment. As to QOL, most improvements seen at 12 months were lost at 3 years, returning to pre-procedure levels. Only the energy/fatigue domain improvement was kept between the 1- and 3-year visits. Conclusions  Obesity is a chronic relapsing disease. Most effects of TORe are lost at 3 years, and redilation of the GJA occurs. Therefore, TORe should be considered iterative rather than a one-off procedure.
format Online
Article
Text
id pubmed-10219785
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Georg Thieme Verlag KG
record_format MEDLINE/PubMed
spelling pubmed-102197852023-05-27 Long-term follow-up after transoral outlet reduction following Roux-en-Y gastric bypass: Back to stage 0? Brunaldi, Vitor Ottoboni Peixoto de Oliveira, Guilherme Henrique Kerbage, Anthony Ribas, Pedro Henrique Nunes, Felipe Faria, Galileu de Moura, Diogo Riccioppo, Daniel Santo, Marco de Moura, Eduardo Endosc Int Open Background and study aims  Significant weight regain affects up to one-third of patients after Roux-en-Y gastric bypass (RYGB) and demands treatment. Transoral outlet reduction (TORe) with argon plasma coagulation (APC) alone or APC plus full-thickness suturing TORe (APC-FTS) is effective in the short term. However, no study has investigated the course of gastrojejunostomy (GJ) or quality of life (QOL) data after the first post-procedure year. Patients and methods  Patients eligible for a 36-month follow-up visit after TORe underwent upper gastrointestinal endoscopy with measurement of the GJ and answered QOL questionnaires (RAND-36). The primary aim was to evaluate the long-term outcomes of TORe, including weight loss, QOL, and GJ anastomosis (GJA) size. Comparisons between APC and APC-FTS TORe were a secondary aim. Results  Among 39 eligible patients, 29 returned for the 3-year follow-up visit. There were no significant differences in demographics between APC and APC-FTS TORe groups. At 3 years, patients from both groups regained all the weight lost at 12 months, and the GJ diameter was similar to the pre-procedure assessment. As to QOL, most improvements seen at 12 months were lost at 3 years, returning to pre-procedure levels. Only the energy/fatigue domain improvement was kept between the 1- and 3-year visits. Conclusions  Obesity is a chronic relapsing disease. Most effects of TORe are lost at 3 years, and redilation of the GJA occurs. Therefore, TORe should be considered iterative rather than a one-off procedure. Georg Thieme Verlag KG 2023-05-26 /pmc/articles/PMC10219785/ /pubmed/37251791 http://dx.doi.org/10.1055/a-2075-1198 Text en The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited.
spellingShingle Brunaldi, Vitor Ottoboni
Peixoto de Oliveira, Guilherme Henrique
Kerbage, Anthony
Ribas, Pedro Henrique
Nunes, Felipe
Faria, Galileu
de Moura, Diogo
Riccioppo, Daniel
Santo, Marco
de Moura, Eduardo
Long-term follow-up after transoral outlet reduction following Roux-en-Y gastric bypass: Back to stage 0?
title Long-term follow-up after transoral outlet reduction following Roux-en-Y gastric bypass: Back to stage 0?
title_full Long-term follow-up after transoral outlet reduction following Roux-en-Y gastric bypass: Back to stage 0?
title_fullStr Long-term follow-up after transoral outlet reduction following Roux-en-Y gastric bypass: Back to stage 0?
title_full_unstemmed Long-term follow-up after transoral outlet reduction following Roux-en-Y gastric bypass: Back to stage 0?
title_short Long-term follow-up after transoral outlet reduction following Roux-en-Y gastric bypass: Back to stage 0?
title_sort long-term follow-up after transoral outlet reduction following roux-en-y gastric bypass: back to stage 0?
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219785/
https://www.ncbi.nlm.nih.gov/pubmed/37251791
http://dx.doi.org/10.1055/a-2075-1198
work_keys_str_mv AT brunaldivitorottoboni longtermfollowupaftertransoraloutletreductionfollowingrouxenygastricbypassbacktostage0
AT peixotodeoliveiraguilhermehenrique longtermfollowupaftertransoraloutletreductionfollowingrouxenygastricbypassbacktostage0
AT kerbageanthony longtermfollowupaftertransoraloutletreductionfollowingrouxenygastricbypassbacktostage0
AT ribaspedrohenrique longtermfollowupaftertransoraloutletreductionfollowingrouxenygastricbypassbacktostage0
AT nunesfelipe longtermfollowupaftertransoraloutletreductionfollowingrouxenygastricbypassbacktostage0
AT fariagalileu longtermfollowupaftertransoraloutletreductionfollowingrouxenygastricbypassbacktostage0
AT demouradiogo longtermfollowupaftertransoraloutletreductionfollowingrouxenygastricbypassbacktostage0
AT riccioppodaniel longtermfollowupaftertransoraloutletreductionfollowingrouxenygastricbypassbacktostage0
AT santomarco longtermfollowupaftertransoraloutletreductionfollowingrouxenygastricbypassbacktostage0
AT demouraeduardo longtermfollowupaftertransoraloutletreductionfollowingrouxenygastricbypassbacktostage0